Endologix, Inc. to Present at the Stifel Healthcare Conference

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel Healthcare Conference at 3:00 p.m.

Metadata
Provider: 
Business Wire, Inc.
Retrieved on: 
Monday, November 11, 2019
Information
Tags: 
Surgery, Medical devices, Health, Cardiology, Medical Supplies, Angiology, Circulatory system, Cardiovascular system, Aorta, Vascular surgery, IgG4-related disease, Vascular diseases, RTT
Geotags: 
California, NEW YORK, United States
⚠ generated by AI ↴
Organisation: 
ENDOLOGIX, INC.
Summary
Key Points: 
  • Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel Healthcare Conference at 3:00 p.m.
  • A live webcast of the presentation will be accessible through the Investors section of the Companys website at www.endologix.com and will be available for replay following the event.
  • AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.
  • The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States.


Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel Healthcare Conference at 3:00 p.m. ET on Tuesday, November 19, 2019 in New York, NY.

A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.endologix.com and will be available for replay following the event.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. For more information, visit www.endologix.com.

Copyright: 
Copyright Business Wire 2019